In the latter case, the PIK3CA mutation may not be driving tumour progression or maintenance, and as such either PI3K targeted therapy will be less effective, or drug resistance will develop more quickly as the tumour uses the co-existing driver mutation to overcome the effects of the drug. The gene discussed is PIK3CA; the disease is neoplasm.